South Korean pharmaceutical majors increase H1 R&D expenditure to over 100 billion won each

Major South Korean pharmaceutical firms have each invested over 100 billion won in research and development during the first half of 2026. This sustained high-level capital allocation reflects a strategic shift toward drug innovation and global market competitiveness, though specific pipeline outcomes remain unverified.